Can Low-Dose Lithium Prevent Cognitive Decline in Older Adults at Risk for Dementia
A completed Phase 4 trial tests whether lithium carbonate can slow cognitive decline in older adults with mild cognitive impairment.
Summary
Alzheimer's disease remains incurable and devastates memory and independence in millions of older adults. Laboratory and observational data have long hinted that lithium — a mood-stabilizing mineral used in psychiatry — may protect the brain against dementia by reducing neuroinflammation and blocking pathological protein accumulation. This completed Phase 4 trial, led by Dr. Ariel Gildengers, enrolled 83 older adults with mild cognitive impairment (MCI) — a high-risk group for conversion to full dementia — and randomized them to lithium carbonate or placebo. The trial ran from early 2018 through mid-2024, providing one of the most direct human tests of lithium's potential as a dementia-prevention agent. Results from this trial could clarify whether repurposing this inexpensive, well-understood drug offers a practical strategy for preserving cognitive healthspan in aging populations.
Detailed Summary
Alzheimer's disease is the leading cause of dementia in adults over 65, stripping away memory, autonomy, and identity with no available cure. Identifying interventions that delay or prevent its onset is among the most urgent priorities in aging medicine. Lithium, a trace element and established psychiatric drug, has attracted serious attention as a candidate neuroprotective agent based on decades of mechanistic and epidemiological evidence.
Preclinical studies show lithium inhibits glycogen synthase kinase-3 beta (GSK-3β), an enzyme that promotes tau hyperphosphorylation and amyloid production — two hallmarks of Alzheimer's pathology. Population-level data suggest people who drink water with higher natural lithium concentrations or who take lithium for bipolar disorder have lower rates of dementia, adding ecological plausibility to the mechanistic case.
This Phase 4 randomized controlled trial, registered as NCT03185208 and sponsored by Ariel Gildengers, MD at the University of Pittsburgh, enrolled 83 older adults diagnosed with mild cognitive impairment. Participants were randomized to oral lithium carbonate or matched placebo capsules. The trial ran from February 2018 through August 2024, providing approximately six years of follow-up — a duration sufficient to detect meaningful cognitive trajectory differences in an MCI cohort.
The trial was conducted under the Alzheimer's Prevention Trials consortium, lending it infrastructure and credibility. As a completed study, it now stands as one of the most rigorous direct human tests of lithium's anti-dementia potential in a population already on the cognitive decline trajectory.
Caveats are important: the modest sample size of 83 limits statistical power to detect small but clinically meaningful effects. The summary here is based solely on the publicly available abstract and trial registration record; full results, including cognitive outcome data and safety profiles, have not yet been published in peer-reviewed form. Clinicians should await the primary publication before drawing practice-changing conclusions.
Key Findings
- Phase 4 RCT directly tested lithium carbonate vs. placebo for preventing cognitive decline in 83 older adults with mild cognitive impairment.
- Trial duration spanned over six years (2018–2024), long enough to detect meaningful changes in MCI-to-dementia conversion rates.
- Lithium inhibits GSK-3β, reducing tau phosphorylation and amyloid accumulation — core Alzheimer's pathological mechanisms.
- Epidemiological data link higher dietary lithium exposure to lower dementia prevalence, supporting this trial's rationale.
- Results could support repurposing an inexpensive, well-characterized drug as a dementia prevention strategy for at-risk elders.
Methodology
This is a completed Phase 4, randomized, placebo-controlled trial enrolling 83 older adults with mild cognitive impairment. Participants received oral lithium carbonate or placebo capsules over a period running from February 2018 to August 2024. The trial was conducted within the Alzheimer's Prevention Trials network.
Study Limitations
The sample size of 83 participants limits statistical power to detect modest but clinically meaningful cognitive effects. This summary is based on the abstract and trial registration record only, as full results have not yet been published in a peer-reviewed journal. Generalizability may be constrained by the specific MCI population enrolled and the dosing regimen used.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: